Skyhawk’s $80M Celgene deal expands remit to autoimmune
- maura169
- Nov 12, 2019
- 1 min read
In Skyhawk’s fifth deal of the year, the company is moving into a new therapeutic area and adding $80 million to its cash reserve. Skyhawk partnered with Celgene to discover and develop small molecules for autoimmune disease and cancer against hard-to-drug targets that have been clinically validated, or genetically associated with a disease.
For more information visit:
SKYHAWK MEDIA CONTACT:
Maura McCarthy
Comentários